Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah still short, what m&a are u on about. Nobody, sane, would want this dog and shp bod has no money left to overpay for any more acquisitions. It is possible that something more sinister is keeping buyers away or it is rubber band game still on. Till bod comes up with spin-off opposition sp will yo-yo, IMO. That spin-off will come I have no doubt, bod is all for relentless financial engineering, but how will the market see it? How likely is that any part ( overpriced and underperforming) of shp is going to demand premium in Jumble sale ? Not massive imo, bta, volatility must exist so some can make money while most will loose. Again, if you are not leverage trading and have no marg to worry about, just watch how things unfold and you are likely to do ok eventually. Most loved becomes most unloved and the other way around. That said im not likely to short apple any time soon. Mulder, just patience and balls, if not hedging will make you a bit of dosh.
BTG P/E 85 Abcam P/E 49 AstraZeneca P/E 18 GSK P/E 15 Novartis P/E 29 Merck P/E 54 Pfizer P/E 22 Shire? P/E of just 9 and yet this is one the market chooses to hammer and sees as over-valued! Highlights the dirty and rogue market.
**Ornskov said a decision on whether to spin off Spire�s neuroscience drugs, which analysts say could be worth up to $8.5 billion, would be made by year-end. The franchise, which mainly addresses attention deficit hyperactivity disorder (ADHD), achieved growth of 12 percent. It successfully launched Mydayis in August and the once-daily ADHD drug had been prescribed to more than 11,000 patients by Oct. 17, he added. Shire has reviewed its manufacturing portfolio after the Baxalta deal, and Ornskov said it had identified $100 million in annual savings from 2019. The company reported a 20 percent rise in non-GAAP earnings per share, its preferred measure, of $3.81 on total revenue of $3.70 billion, and reiterated its guidance for the year.
Fact is Q3 results were better than the market expected yet the rally was pathetic. $1 BILLION in FREE CASH FLOW! Debt is coming down nicely. There was nothing to justify the current share price. >2% down again today for what reason? As soon as the DOW opens the SP crashes. Credit Suisse' and their expert analysts just gave an update saying even in a worst case scenario re: Roche and competition concerns Shire is wildly undervalued and is worth 4600p+ None of the brokers have a target as low as the current SP with most re-iterating 5000p; others as high as 6000p Are the shorters saying all the brokers and Credit Suisse analysts are talking rubbish or is that they are privy to inside information/insider dealing? I favour the latter.
you are very negative for a holder. if you think this will not recover till feb then why are you still holding? sell and move on to better stocks, even if you make huge loss here, u can recover in other better companies in next 2 to 3 months. you can come back to shp and hold more shares and enjoy the rise of feb as you predict it. or you are another shorter just saying you hold shares here ..... I wonder
Mulder, Sorry, I can't agree with you. Lack of Dirs buying and general unrest does not mean that 'it is likely that M&A discussions are going on'. There might be so,me but it is extremely wishful thinking to assume this is likely. Don't get me wrong, I would love that to be the case but I do not see anyone going for SHP until after the new US tax rules are introduced (whenever that is!!). I would be surprised to see much upside in the SP before the Feb/March when the FY results are out. Not sure if the spin off plans will bring much joy either.
Yet again the trend continues. I’m totally in the dark as to reasons with this trading at what would appear gift prices. Does the market know something?
Still here I assume and shorting? The mini rally lasted a day or two and then gets hammered again without any justification or logic. I would like the short sellers to give me 3 good reasons why they believe Shire is 'overvalued' trading as it is on a historic and sector low P/E of 9. It smacks of inside information and insider dealing to me and we have said as much directly to the FCA, CEO, IR and intelligence teams.
No. The CEO Ornskov has committed to having finalised plans regarding the spin off by the end of the year. So could be anytime. The lack of director buys and high degree of unrest among major investors and activists + low SP means discussions are likely to be going on regarding M&A.
Presumably this is just speculation/wishful thinking?
I understand we should be hearing news about the spin off very soon. Chance of a bid also. Should see a sharp re-rating upwards.
Yet again on opening Nasdaq starts to drive price downwards. I wonder if there are forces at work to keep this share at Year lows prior to bid received? Maybe wishful thinking but looking very suspicious
Starting to become suspicious of the constant downward pressure when we open stateside. The consistent spiralling of price once they open is becoming the normal. Very frustrating.
Even if Shire lost its entire Haematology business to competitors like Roche it is still trading at a steep discount to peers. Brokers like Credit Suisse said only last week even in a worst case scenario Shire should be trading at 4600p+ Illogical and irrational market behaviour again.
Correction, sinister not canister
I�ve not reduced my short since I�ve told you, but reduced long. Maybe that is what did it for so today? Btw, there is minuscule short here, under 2m shares on Nasdaq that would take less than 3days ( avr. Vol.) to close. Similar on lse. Again, it is absence of buyers that is feeding the sentiment. I find non GAAP reporting needlessly irritating, others might see it canister. Also with fed and boe expected to rise rates that bits shps RoA and RoE risk v reward is I being reassessed. Tesla, google, Facebook amazon and few others can getaway with having no divi or negligible i well below central blanks base rate, but not shp. On the bright note shp mcap is above of that what ABB has offered for it few years back. In old money that would be �49-�50 sp. Let�s see how it ends day post fed meeting
The mini rally did not last long. notgreedy back shorting?
SHIRE READY TO FLY https://seekingalpha.com/article/4118487-shire-q3-2017-ready-fly **Non GAAP Net Debt has been reduced by $0.92B in Q3/2017, driven by a really strong free cash flow generation of $1.05B. Thus, it looks like that the company will be able to achieve its target of 2-3x net debt to EBITDA leverage by end 2017. Analysis shows that even assuming a conservative 6/8x P/E valuation to Rare Disease and Heamophilia franchises, the stock is undervalued by at least 35%.*** Multiples Comparison Lastly, Shire has traded historically at 15.3x NTM (next twelve months) P/E, which was below the Spec pharma group. Today, Shire is trading at a discount to its 5-year average historical P/E on an absolute and relative basis, as shown by the following analysis. In particular, the stock is trading at 9.1x NTM (next twelve months) P/E, which is at 40% of discount vs. its historical valuation.****
Large discrepancy of 1% between Nasdaq and FTSE today. Strange.
It always had legs MC. Preventing the walk/run were the shackles of crazy Shorts.
This now looks like it has a good set of legs !
whined up in wanted direction, despite Barclays �change of hart�. https://www.marketwatch.com/story/fund-manager-analysts-make-the-case-for-this-loathed-pharma-stock-2017-10-30
WIM, No I didn't sell in the end. Wish I had and then I could have bought in a bit lower. Who knows where it will go from here. Hoping for a bid but can't see anything soon as the US needs to sort out its tax reform so the big Pharmas know where they stand. Maybe 2018 will be Shire's year.
Yet another $1b of debt paid off and balance sheet looking better every quarter, but shares languishing at year lows, how very strange. Great results especially as issues with supply, stonking buy for me, I’ve topped up following fridays opportunity and will now be patient for momentum to inevitably build.
One of the biggest problem with shorting is the automatic control and manipulation it brings to a share price regardless of fundamentals and the lock down that follows. That and the fact you will benefit from bad news and the misfortune of a company failing. Having said that those companies that are wildly overvalued trading on ridiculous P/E's of up to 200 as highlighted yesterday deserve to be shot down. Strange how those companies are rarely targeted by shorters.